Neptune Reports First Quarter Results

Neptune Reports First Quarter Results

Nutraceutical Quarterly Revenues Increased by 43%

LAVAL, Quebec, July 16, 2012 (GLOBE NEWSWIRE) -- Neptune Technologies &
Bioressources Inc. ("Neptune" or the "Corporation") (Nasdaq:NEPT) (TSX:NTB)
reports today its consolidated financial results for the three month ended May
31, 2012.

Three month ended May 31, 2012 Financial Results

Nutraceutical Business Results

  *Nutraceutical revenues increased by 43% to $6,139,000, for the three-month
    period ended May 31, 2012, up from $4,283,000 achieved during the
    corresponding period ended May 31, 2011.
  *EBITDA from nutraceutical business for the three-month period ended May
    31, 2012 increased by 67% to $1,289,000, up from $774,000 obtained during
    the corresponding period ended May 31, 2011.
  *Net income from nutraceutical business reached $48,000 for the three-month
    period ended May 31, 2012, compared to a net loss of ($70,000) for the
    corresponding period ended May 31, 2011.

Consolidated Results

  *Revenues increased by 44% to $6,153,000 for the three-month period ended
    May 31, 2012, up from $4,283,000 achieved during the corresponding period
    ended May 31, 2011.
  *Consolidated EBITDA for the three-month period ended May 31, 2012 was
    $142,000, compared to ($167,000) obtained during the corresponding period
    ended May 31, 2011.
  *Earnings for the three-month period ended May 31, 2012 resulted into a net
    loss of ($1,695,000) compared to a net loss of ($1,258,000), for the
    corresponding period ended May 31, 2011.

"In the first quarter, we once again executed a triple play – simultaneously
investing for growth and IP protection, increasing market share, and investing
in research and development programs. With this drive, we entered this new
fiscal year exceptionally well positioned to maintain our operational
performances, execute our growth strategy, and continue delivering positive
results" said Frederic Harland, Director of Finance.

"Neptune had a strong and record-breaking fiscal year 2012 and the momentum
has kept on in the first quarter. There's no doubt that Neptune Krill Oil is
completely transforming the Omega-3 industry and that NKO^TM has a profound
effect on transforming the way we consume Omega-3. Our customers and partners
have these facts in their sights and are embracing Neptune's vision, strategy
and best-of-breed product to capitalize on them and realize the full potential
of NKO^TM" said André Godin, CFO.

About Neptune Technologies & Bioressources Inc.

Neptune is an industry-recognized leader in the innovation, production and
formulation of science-based and clinically proven novel phospholipid products
for the nutraceutical and pharmaceutical markets. The Company focuses on
growing consumer health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive approach to
managing health and preventing disease. The Company sponsors clinical trials
aimed to demonstrate its product health benefits and to obtain regulatory
approval for label health claims. Neptune is continuously expanding its
intellectual property portfolio as well as clinical studies and regulatory
approvals. Neptune's products are marketed and distributed in over 30
countries worldwide.

About Acasti Pharma Inc.

Acasti Pharma (TSXV:APO) is developing a product portfolio of proprietary
novel long-chain omega-3 phospholipids. Phospholipids are the major component
of cell membranes and are essential for all vital cell processes. They are one
of the principal constituents of High Density Lipoprotein (good cholesterol)
and, as such, play an important role in modulating cholesterol efflux. Acasti
Pharma's proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have
substantial health benefits and which are stabilized by astaxanthin, a potent
antioxidant. Acasti Pharma is focusing initially on treatments for chronic
cardiovascular and cardiometabolic conditions within the over-the-counter,
medical food and prescription drug markets.

About NeuroBioPharm Inc.

NeuroBioPharm is pursuing pharmaceutical neurological applications, and a
clinical study for a medical food product with a multinational partner is
already initiated. The development of a prescription drug candidate is
currently in progress. Advanced clinical development and commercialization is
planned to be carried out with multinational partners.

"Neither Nasdaq nor the TSX nor its Regulation Services Provider (as that term
is defined in the policies of the TSX) accepts responsibility for the adequacy
                        or accuracy of this release."

Statements in this press release that are not statements of historical or
current fact constitute "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities
laws. Such forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the actual results
of the Company to be materially different from historical results or from any
future results expressed or implied by such forward-looking statements. In
addition to statements which explicitly describe such risks and uncertainties,
readers are urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or "plans" to be
uncertain and forward-looking. The forward-looking statements contained herein
are also subject generally to other risks and uncertainties that are described
from time to time in the Company's reports filed with the Securities and
Exchange Commission and the Canadian securities commissions.

CONTACT: Neptune Contact:
         Neptune Technologies & Bioressources Inc.
         Andre Godin, CFO
         +1.450.687.2262
         a.godin@neptunebiotech.com
         www.neptunebiotech.com
        
         Howard Group Contact:
         Dave Burwell
         (888) 221-0915
         dave@howardgroupinc.com
         www.howardgroupinc.com
 
Press spacebar to pause and continue. Press esc to stop.